REVIEW ARTICLE

The Role of Artificial Intelligence in the Pharmaceutical Sector: A Comprehensive Analysis of its Application from the Discovery Phase to Industrial Implementation

Prajwal S Shinde[1*], Ashish Y Pawar[1], Swati G Talele[2]

[1]Department of Pharmaceutical Sciences, MGV'S Pharmacy College, Panchavati, Nashik, Affiliated to Savitribai Phule Pune University, Pune, Maharashtra, India.

[2]Department of Pharmaceutical Sciences, Sandip Institute of Pharmaceutical Sciences, Nashik, Affiliated to Savitribai Phule Pune University, Pune, Maharashtra, India.

Received: 20th August, 2023; Revised: 17th October, 2023; Accepted: 28th November, 2023; Available Online: 25th December, 2023

ABSTRACT

The incorporation of artificial intelligence (AI) technology into the pharmaceutical sector is a groundbreaking revolution, promising to enhance drug development significantly by boosting speed, efficiency, and effectiveness. This transformative journey encompasses several key facets, notably the sophisticated analysis of complex data, the optimization of drug delivery systems, the acceleration of drug discovery, the identification of valuable biomarkers and drug candidates, and the fine-tuning of treatment outcomes. Beyond these crucial strides, AI is reshaping healthcare at large, elevating decision-making processes, and deepening our understanding of diseases and pharmaceuticals. The broader domains within this AI-driven transformation encompass themes such as "Revolutionizing Pharmaceutical Product Development Through AI," where AI platforms like the Chemputer successfully synthesize compounds and estimate granulation completion times, improving production efficiency. In "Transforming Pharmaceutical Manufacturing with AI, "AI optimizes manufacturing processes, further enhancing efficiency." Enhancing Clinical Trial Design Through AI" harnesses AI to improve patient selection and adherence, utilizing genome and exposome profiles for precise and efficient clinical trials. AI also proves valuable in preclinical phases, predicting lead compounds. Moreover, AI extends its influence to brand recognition and market positioning of pharmaceutical products, leveraging technology and e-commerce platforms for distinct product identities and effective marketing strategies. In "Convergence of AI and Nanomedicine," AI delves into complex formulation development, optimizing drug delivery methods via molecular analysis and simulation tools. Furthermore, AI's role in addressing challenges in the pharmaceutical market, such as reducing financial burdens and risks related to virtual screening, is pivotal. The sector's substantial growth and its integration into pharmaceutical companies' strategies through collaborations signify a promising future for AI in healthcare.In summary, the incorporation of AI in the pharmaceutical industry holds immense potential for enhancing production processes, clinical trial design, market positioning, nanomedicine, and overall industry efficiency. These collective advancements mark a transformative era in pharmaceutical innovation and patient care.

Keywords: Artificial Intelligence, Drug discovery, Drug development, Nanotechnology.

International Journal of Drug Delivery Technology (2023); DOI: 10.25258/ijddt.13.4.70

How to cite this article: Shinde PS, Pawar AY, Talele SG. The Role of Artificial Intelligence in the Pharmaceutical Sector: A Comprehensive Analysis of its Application from the Discovery Phase to Industrial Implementation. International Journal of Drug Delivery Technology. 2023;13(4):1578-1584.

Source of support: Nil.

Conflict of interest: None

INTRODUCTION

The field of healthcare is undergoing a significant transformation through the rapid development of digital healthcare technologies like 3D printing, artificial intelligence (AI), robotics, and nanotechnology. This shift is bringing about a range of possibilities, such as minimizing mistakes, enhancing patient outcomes, and effectively monitoring data across time. In this digital era of healthcare, AI techniques spanning from machine learning (ML) to deep learning (DL) play a pivotal role in various aspects of well-being. These technologies are instrumental in advancing novel clinical procedures, managing patient data and medical histories, and addressing a wide array of medical conditions. The biopharmaceutical and drug industries have not only brought about new and creative technologies and machines, but they have also pioneered fresh ideas and interpretations in the fields of chemical and mechanical engineering. However, there's a pressing need for innovative mechanical solutions in the pharma industry

**Author for Correspondence: prajwalksshinde25@gmail.com*

for the easy making of human medicines. Making complex medications that are both safe and suitable for large-scale use has proven to be difficult due to technological limitations.[1]

The current way we prescribe medications depends on a "one size fits all" approach, but there are several important areas in medicine where new methods are needed, leading to the development of fresh ways to create drugs. Recent advancements in genomics and diagnostics have opened the door for innovative pharmaceutical products and approaches. These use new analysis and measurement tools. The pharmaceutical industry could benefit from personalized medications. Unfortunately, medical planning and manufacturing progress are insufficient for personalized medicine. Therefore, there's a necessity for new ways of manufacturing and producing adaptable technology and machinery in the pharma sector.

The rise of AI is causing changes in how medical exams and training are done. Doctors can actively contribute to the development of AI for its application in medicine and pharmaceuticals. By doing so, they ensure that AI's potential to greatly enhance medical care is fully realized. In the pharmaceutical field, AI is currently employed in four primary ways. Firstly, it helps assess the seriousness of diseases and predicts whether a patient will respond well to treatment even before the treatment is given. Second, AI prevents or resolves treatment complications. Thirdly, it serves as an assisting tool during medical procedures or surgeries performed on patients. AI and also plays a broader role in handling and studying large amounts of information, known as big data. It is a new concept that involves collecting large datasets and using advanced methods to gain new insights.[2]

Increased data volume is making prior data storage methods outdated in the pharmaceutical industry. Big data offers a significant opening for comprehensive research by delving into data mining within this industry. Managing data after collection in three steps improves pharmaceutical manufacturing. This process involves gathering and organizing large and diverse sets of data, making sure the data has a consistent structure, and then analyzing the data using various tools to produce a final result. This finding can help choose compounds and medicine to develop and processes to use for maximum efficiency. AI-driven technology is increasingly being embraced to address seemingly small yet significant challenges within the drug development sectors. This is primarily attributed to the notable progress, expansion, and assimilation of vast data resources that enable the extraction of valuable insights. As a result of these developments, there arises a distinct necessity to compile a comprehensive article that thoroughly examines the collective impact of big data and AI with machine learning on the entire spectrum of drug discovery and development.[3]

Drug Discovery

The pool of a large number of molecules is the major challenge in identifying suitable molecules to target the specific disease. The complexity and vastness of this space contribute to the difficulties and expenses associated with the drug development process. However, the AI can play a crucial role in addressing these challenges as given in Figure 1.

AI can contribute to drug development in several ways:

- Recognition of Hit and Lead Compounds: AI can assist in identifying potential drug candidates by recognizing molecules that show promise as "hits" or "leads." This is a crucial step in the drug discovery process, as it narrows down the pool of potential candidates for further investigation.
- Quicker Validation of Drug Targets: AI can expedite the validation of drug targets. Identifying and validating appropriate targets for drug intervention is a crucial early step in the drug development process. AI tools can analyze biological data and help researchers identify and prioritize potential drug targets more efficiently.
- Optimization of Drug Structure Design: AI can aid in the optimization of drug structures. Once potential drug candidates are identified, AI algorithms can assist in designing and refining the chemical structures of these compounds for improved efficacy, safety, and other desirable properties.
- Time and Cost Efficiency: By automating and streamlining various stages of drug development, AI has the potential to significantly reduce the time and cost associated with bringing new drugs to market.

In summary, the integration of AI in drug development processes holds the promise of accelerating the identification of potential drug candidates, validating drug targets, and optimizing drug structures. This has the potential to make drug development more efficient, and cost-effective, and ultimately contribute to the discovery of new and improved therapeutic agents. Figure 2 shows applications of AI in drug discovery.[4]

DeepChem is an open-source deep-learning framework specifically designed for drug discovery and cheminformatics. It provides tools and models to assist in various aspects of drug discovery, including virtual screening, compound generation, and predictive modeling. One type of model that can be implemented for drug discovery tasks is a multi-layer perceptron (MLP).

Quantitative Structure-Activity Relationship (QSAR) is a field in cheminformatics and computational chemistry where mathematical models are built to predict the biological activity or properties of chemical compounds based on their structural



Figure 1: Challenges overcome by use of artificial intelligence



Figure 2: The pharmaceutical industry uses AI in drug discovery, development and administration

features. Deep neural networks (DNNs) or deep learning techniques have been increasingly applied to QSAR analysis due to their ability to capture complex relationships in data. A "DeepNeuralNetQSAR" tool or project could imply the use of deep neural networks for QSAR predictions.

Neural graph fingerprints are a type of representation used in machine learning for predicting the properties of molecules, especially in the field of cheminformatics and drug discovery. Graph-based methods are particularly well-suited for capturing the structural information of molecules, which is crucial for understanding their properties and activities.

Here's a brief overview of how neural graph fingerprints work :

- Graph Representation: Molecules can be represented as graphs, where atoms are nodes and bonds are edges. This representation captures the spatial arrangement of atoms in a molecule and its connectivity.
- Neural Graph Fingerprinting: Neural networks are employed to learn a fixed-size vector representation, often called a fingerprint, for each molecule. These fingerprints encode the structural information in a way that is amenable to machine learning.
- Property Prediction: The learned fingerprints are then used as input features for a machine learning model, such as a neural network, to predict various properties or activities of interest. These could include properties like solubility, toxicity, or affinity to a specific biological target.
- Training and Validation: The model is trained on a dataset of molecules with known properties.

One advantage of neural graph fingerprints is their ability to capture complex structural information, including spatial relationships between atoms in a molecule. This can be crucial for predicting properties that depend on the three-dimensional arrangement of atoms.[5]

Bioinformatics in Drug Development Process

Bioinformatics leverages efficient methods to streamline and reduce the time and expenses linked to drug development. It facilitates a rapid acceleration in drug manufacturing across different phases of the drug discovery process. Several databases containing information about drug targets are available, such as Super Target, Therapeutic Target Database, Drug Bank, CSNAP etc. In simpler terms, bioinformatics uses cost-effective techniques to speed up drug development and relies on various databases for valuable information about drug targets.

Due to the swift expansion in the number of potential drug targets, bioinformatics plays a crucial role in identifying and analyzing these targets, with the aim of predicting potential drugs. Once potential drugs are identified, it's essential to confirm that they interact effectively with the intended target. High-throughput screening, simulation and molecular docking is used in bioinformatics to validate targets efficiently. By doing so, bioinformatics significantly decreases the likelihood of drug candidates failing during clinical testing. Bioinformatics methods improve drug candidate success rates, making drug discovery more cost-effective. Table 1 lists drug discovery and development AI tools in the Pharmaceutical field.[6]

Revolutionizing Pharmaceutical Product Development Through AI

AI is playing a pivotal role in advancing the development of pharmaceutical products. Once a new drug molecule is discovered, it needs to be formulated into a suitable dosage form that ensures optimal delivery. Traditionally, this formulation process involved a trial-and-error approach, but AI is revolutionizing this method.

AI offers a set of computational tools that can effectively address challenges in formulation design. These challenges encompass a range of issues like stability, dissolution, and porosity. Through the utilization of quantitative structure-property relationship (QSPR) models, AI can provide solutions to these challenges.

AI-powered decision-support tools use to choose excipient types, compositions, and quantities. These decisions are based on the specific physicochemical characteristics of the drug. Additionally, these AI-driven tools operate within a feedback loop, enabling continuous monitoring of the entire formulation process. As new information is gathered, the AI system can make intermittent adjustments to optimize the process.

In essence, AI is replacing the conventional trial-and-error approach in pharmaceutical formulation by leveraging computational tools to enhance decision-making and streamline the development of drug products.[7]

Transforming Pharmaceutical Manufacturing with Artificial Intelligence

Modern factories try to translate human knowledge to machines as processes become more complex and demand for efficiency

Table 1: Web-based drug development ai tools

Tools	*Applications*
ChemSAR	SAR Modelling
Deep Screening	Virtual screening using deep learning
MLViS	Virtual screening using machine learning
PPB2	Polypharmacology target prediction

and quality rises. This evolution in manufacturing practices is changing production management. AI in manufacturing could benefit the pharmaceutical industry. Computational fluid dynamics (CFD) uses Reynolds-Averaged Navier-Stokes solvers to analyze agitation and stress in stirred tanks. Automation streamlines multiple pharmaceutical processes.

Large Eddy simulations and direct numerical simulations solve complex manufacturing flow problems using sophisticated methods. These advanced methods help solve complex production flow issues. The novel Chemputer platform automates molecule synthesis and manufacturing using chemical assembly scripting language and chemical codes. It successfully synthesizes sildenafil and rufinamide. Both purity as well as yield match with manual synthesis.

AI technologies have proven effective in efficiently estimating the time needed for granulation completion in granulators spanning capacities from 25 to 600 litres. This approach utilizes technology along with neuro-fuzzy logic to establish meaningful connections between critical variables and their corresponding outcomes. Through this analysis, they formulated polynomial equations that predict essential factors like the optimal amount of granulation fluid to add, the necessary speed, and the impeller diameter. These predictions are applicable to both granulators that are geometrically similar and those that differ in shape and size.[8]

Algorithms for Machine Learning in Artificial Intelligence

Artificial intelligence employs various learning algorithms during the drug development process, as illustrated in Figure 3. It includes a broad range of AI algorithms that are essential to the drug development process. These algorithms include dimensionality reduction techniques, decision tree approaches, ensemble methods, instance-based techniques, Bayesian methods, and different types of artificial neural networks.



Figure 3: Learning algorithms of AI for the process of drug development

They leverage Bayesian networks and belief networks, both structured as directed acyclic graphs. In these networks, nodes represent different variables such as molecular descriptors and activity data, while edge weights signify conditional dependencies. Although computationally expensive, Bayesian algorithms enable modeling of diverse relationships among variables, encompassing linear, stochastic, nonlinear, and combinatorial interactions.

Memory- or instance-based "lazy" algorithms store all training examples until they classify new query instances. The most common method is kNN. Anticipatory algorithms like radial basis function networks generalize before new queries. Self-organizing maps are competitive learning algorithms that preserve topological properties of input spaces with many nodes.[9]

Enhancing Clinical Trial Design Through Artificial Intelligence

Clinical trials aim to verify the safety and effectiveness of a drug in human subjects for a specific medical condition. These trials demand a significant investment of around 6 to 7 years and substantial financial resources. Regrettably, the pharmaceutical industry experiences a daunting reality where only one out of every ten compounds that advance to these trials ultimately achieves the necessary approvals. This staggering attrition represents a substantial setback and financial burden for the industry.

The reasons behind these failures often stem from factors such as improper patient screening, insufficient adherence to technical prerequisites, and inadequate infrastructure. Nevertheless, the considerable wealth of digital medical data presents an opportunity to mitigate these failures through the integration of AI. In essence, leveraging AI could lead to a reduction in these setbacks by enhancing patient selection, meeting technical criteria, and improving overall trial infrastructure.

Approximately one-third of the duration of a trial is consumed by the process of enrolling patients. The effectiveness of a clinical trial's outcome hinges significantly on the ability to successfully recruit appropriate participants. In instances where patient recruitment falls short, it results in a substantial 86% of clinical trial failures. AI could help recruit patients with a specific medical condition during different phases of clinical trials such as phase II and III. By utilizing patient-specific genome AI can aid in the identification of a specific population affected by the disease. This approach enables the primary prediction of viable targets for drugs within the selected patient group, enhancing the precision and efficiency of clinical trials.

The use of various facets of AI, including ML and other methods, can contribute significantly to the preclinical identification of molecules and the anticipation of potential lead compounds even before commencing clinical trials. This approach aids in the early identification of lead molecules that have a higher likelihood of successfully navigating clinical trials, taking into account the specific patient population that has been targeted for the study.

Patient attrition, responsible for causing 30% of clinical trial failures, imposes extra recruitment needs and results in wasted resources. This challenge can be mitigated through vigilant patient monitoring and support in adhering to the trial protocol. To address this, Ai Cure developed mobile software that effectively tracked medication adherence among schizophrenia patients in a clinical trial like phase II. Implementing this technology increased patient adherence by 25%, ensuring clinical trial success.[10]

AI In Prediction of Toxicity

The prediction of drug toxicity is indeed a crucial step in drug development to ensure the safety of potential therapeutic agents. Various methods, including *in-vitro* assays and computational tools, are employed to assess the toxicity of drug molecules. Here's a brief overview of the mentioned web-based tools:

LimTox

- Purpose: LimTox is designed to predict the toxicity of small drug-like molecules.
- Features: It employs machine learning models trained on diverse toxicity endpoints and provides predictions for different toxicity classes.
- Use: Researchers can input molecular structures to obtain predictions on potential toxicity.

Pharmacokinetics and Chemistry of Small Molecules (pkCSM)

1. Purpose:pkCSM focuses on predicting various pharmacokinetic and toxicological properties of small molecules.
2. Features: It provides information on ADME as well as the toxicity properties of compounds.
3. Use: Researchers can utilize pkCSM to evaluate the pharmacokinetic and toxicity profile of a drug candidate.

ADMETSAR

- Purpose: ADMETSAR is primarily used for predicting absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties of chemical compounds.
- Features: It offers predictions for a range of ADMET-related properties, including toxicity, based on structure-activity relationships.
- Use: Researchers can input molecular structures to obtain information on potential ADMET issues.

Toxtree

- Purpose: Toxtree is a decision support tool for assessing the toxicological properties of chemical compounds.
- Features: It utilizes a decision tree approach and supports various toxicity prediction models.
- Use: Researchers can use Toxtree to evaluate the toxicological profile of a compound and identify potential hazards.

Using these tools can help in the early stages of drug discovery to prioritize compounds with lower toxicity risks, reducing the need for expensive and time-consuming animal studies. However, it's important to note that these tools provide predictions based on computational models, and experimental validation is still necessary to confirm the actual toxicity of a compound. Additionally, the field of predictive toxicology is continually evolving, with ongoing efforts to improve the accuracy and reliability of these computational tools.[11]

The Use of AI in Product Management of Pharmaceutical Products

Market positioning involves creating a unique product identity to attract customers. This strategic element is vital for businesses as it aids in creating a distinctive and individualized brand identity, an indispensable component of nearly all corporate strategies. Viagra's marketing strategy was similar. The company marketed the product beyond erectile dysfunction to address other quality-of-life issues. Leveraging technology and e-commerce platforms has streamlined the process for companies to attain organic brand recognition within the public sphere. Firms utilize search engines as a pivotal technological tool to secure a notable presence in online marketing, contributing to effective product positioning. Companies consistently strive to achieve higher search engine rankings than their competitors, facilitating swift brand recognition within a brief timeframe. Utilizing AI techniques, including DL and ML for the analysis of real-world data (RWD) offers innovative avenues for gaining insights into disease mechanisms and the identification of potential biomarkers. By combining publicly available RWD with experimental data gathered from clinical research and continuously refining AI models through iterative training, there is the chance to improve the research outcomes in the discovery of drug, as depicted in Figure 4.

When combined with neural networks (NNs), alternative methodologies such as particle swarm optimization algorithms and statistical analysis techniques first proposed by Eberhart and Kennedy in 1995, provide a deeper understanding of market dynamics. These techniques play a pivotal role in formulating effective marketing strategies for products, grounded in precise predictions of consumer demand.[12]



Figure 4: AI model for data integration

Convergence of AI and Nanomedicine

Nanomedicines harness the power of nanotechnology and pharmaceuticals to address the diagnosis, treatment, and surveillance of intricate diseases like HIV, cancer, malaria, asthma, and inflammatory conditions. The integration of nanoparticles into drug delivery methods has gained significance due to their heightened effectiveness in therapeutics and diagnostics. Merging nanotechnology with AI presents an opportunity to tackle various challenges in the realm of formulation development, offering potential solutions to complex issues.

A methotrexate nanosuspension was created through computational methods that analyzed the energy arising from drug molecule interactions. This approach helped monitor conditions that might cause the formulation to aggregate. Employing coarse-grained simulation alongside chemical calculations allowed for understanding drug-dendrimer interactions and assessing encapsulation of drug within the dendrimer structure. To learn more about how surface chemistry affects nanoparticle internalization into cells, researchers used software programs like LAMMPS and GROMACS4.

Artificial Intelligence played a role in facilitating the creation of silicasomes, a novel blend of iRGD, a tumor-penetrating peptide. By incorporating iRGD, the transcytosis of silicasomes was enhanced, leading to a substantial three to fourfold increase in their uptake. This advancement resulted in improved treatment efficacy and ultimately contributed to enhanced overall survival rates.[13]

AI in the treatment of COVID-19

AI can repurpose drugs to fight the COVID-19 pandemic in many ways. AI predictive models allow rapid virtual screening of current drugs for COVID-19 treatment. If effective, older drugs can treat COVID-19 patients. Laboratory studies have shown that chloroquine and hydroxychloroquine can treat COVID-19. Also, Remdesivir, an Ebola treatment, works against coronaviruses. COVID-19 patients can also benefit from tocilizumab, an immunosuppressive drug for rheumatoid arthritis. The hardest part of drug repurposing is connecting a drug to its disease. Artificial intelligence can predict COVID-19 inhibitor structures to solve this problem. Early detection and treatment of COVID-19 are crucial. SARS-CoV-2 screening methods include AI and machine learning. ResNet101, SVM, and random forest algorithms are among these advanced methods. These AI methods have improved accuracy and specificity. COVID-19 management has relied on AI methods like COVID-NMA and LitCovid. These apps diagnose COVID-19, track epidemic trends, predict outcomes, and find safe and effective drugs and vaccines.

Various techniques have emerged for addressing COVID-19 diagnostic challenges, including the use of extreme learning machines (ELM), and recurrent neural networks (RNN). Key issues related to COVID-19, such as geographical concerns, high-risk populations, and the interpretation of radiological data, have driven the development of appropriate estimation and prediction models using diverse datasets, both non-clinical and clinical. Using these services allows AI professionals to examine massive datasets, which in turn helps doctors train machines, establish algorithms, and optimize data analysis processes for more rapid and precise responses to the virus. Successfully combating COVID-19 and ultimately defeating it relies heavily on assembling a robust arsenal of platforms, methods, tools and approaches that converge to achieve the desired objectives and, most importantly, save lives.[14]

AI's Impact on the Pharmaceutical Industry

In a bid to reduce the financial burdens and risks related to virtual screening (VS), pharmaceutical firms are turning to AI solutions. The AI sector experienced remarkable growth, surging from $200 million in 2015 to $700 million in 2018, with projections indicating it will soar to $5 billion by 2024. With 40% predicted growth from 2017 to 2024, AI revolutionized the pharmaceutical industry. Many different pharmaceutical firms have invested in AI and are ongoing to do so, as well as collaborate with AI firms to create vital healthcare tools.

The recent upsurge in the utilization of AI in the pharmaceutical sector is showing no signs of slowing down. Recent research indicates that approximately 50% of healthcare companies worldwide are planning to incorporate AI strategies and embrace this technology extensively by the year 2025. More specifically, global pharmaceutical firms will invest further in drug discovery, particularly for chronic and oncological diseases. In the US, chronic illnesses are the leading cause of death. AI is helping to treat them. This approach improves chronic disease management, lowers costs, and improves patient well-being. AI may help treat chronic diseases like cancer, diabetes, chronic kidney disease, fibrosis etc, in the future. AI will improve clinical trial candidate selection, revolutionizing the pharmaceutical industry. AI quickly analyses patient data to find the best candidates for a trial, making clinical trials more effective and efficient. Additionally, AI helps eliminate factors that might hinder clinical trials, reducing the need for large trial groups to compensate for these factors. Organization's will continue to leverage AI for improved patient screening and diagnosis. Experts can use AI to gain insights from MRI and mammogram data, improving diagnostic accuracy. AI and ML will continue to improve drug discovery and manufacturing. AI tools will seamlessly integrate into pharmaceutical and manufacturing processes as they become more accessible. AI will drive future progress.[15]

CONCLUSION

The intersection of AI and the pharmaceutical sector represents a paradigm shift, promising not only faster and more efficient drug development but also a holistic improvement across various stages of the pharmaceutical lifecycle. As technology continues to advance, the potential for further innovations and breakthroughs in this field remains significant. Indeed, the integration of AI technology into the pharmaceutical sector has ushered in a transformative era with far-reaching implications. The synergy between artificial intelligence and the pharmaceutical sector opens up new possibilities for accelerating drug development, optimizing treatments, and shaping the future of healthcare.

REFERENCES

1. Bhattamisra SK, Banerjee P, Gupta P, Mayuren J, Patra S, Candasamy M. Artificial Intelligence in Pharmaceutical and Healthcare Research. Big Data and Cognitive Computing. 2023 Jan 11;7(1):10.
2. Vora LK, Gholap AD, Jetha K, Thakur RR, Solanki HK, Chavda VP. Artificial intelligence in pharmaceutical technology and drug delivery design. Pharmaceutics. 2023 Jul 10;15(7):1916.
3. Rathore AS, Nikita S, Thakur G, Mishra S. Artificial intelligence and machine learning applications in biopharmaceutical manufacturing. Trends in Biotechnology. 2023 Apr 1;41(4):497-510.
4. Pazhayattil AB, Konyu-Fogel G. An empirical study to accelerate machine learning and artificial intelligence adoption in pharmaceutical manufacturing organizations. Journal of Generic Medicines. 2023 Jan 10:17411343221151109.
5. Kumar M, Nguyen TN, Kaur J, Singh TG, Soni D, Singh R, Kumar P. Opportunities and challenges in application of artificial intelligence in pharmacology. Pharmacological Reports. 2023 Feb;75(1):3-18.
6. Patel V, Shah M. Artificial intelligence and machine learning in drug discovery and development. Intelligent Medicine. 2022 Aug 1;2(3):134-40.
7. Javaid M, Haleem A, Singh RP, Suman R. Artificial intelligence applications for industry 4.0: A literature-based study. Journal of Industrial Integration and Management. 2022 Mar 21;7(01):83-111.
8. Boddu RS, Ahamad S, Kumar KP, Ramalingam M, Pallathadka LK, Tupas FP. Analysis of Robotics, Artificial intelligence and Machine learning in the field of healthcare sector. Materials Today: Proceedings. 2022 Jan 1;56:2323-7.
9. Bernstam EV, Shireman PK, Meric-Bernstam F, N Zozus M, Jiang X, Brimhall BB, Windham AK, Schmidt S, Visweswaran S, Ye Y, Goodrum H. Artificial intelligence in clinical and translational science: Successes, challenges and opportunities. Clinical and translational science. 2022 Feb;15(2):309-21.
10. Kolluri S, Lin J, Liu R, Zhang Y, Zhang W. Machine learning and artificial intelligence in pharmaceutical research and development: a review. The AAPS Journal. 2022 Feb;24:1-0.
11. Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug discovery today. 2021 Jan;26(1):80.
12. Kulkov I. The role of artificial intelligence in business transformation: A case of pharmaceutical companies. Technology in Society. 2021 Aug 1;66:101629.
13. Selvaraj C, Chandra I, Singh SK. Artificial intelligence and machine learning approaches for drug design: challenges and opportunities for the pharmaceutical industries. Molecular diversity. 2021 Oct 23:1-21.
14. Cavasotto CN, Di Filippo JI. Artificial intelligence in the early stages of drug discovery. Archives of biochemistry and biophysics. 2021 Feb 15;698:108730.
15. Malandraki-Miller S, Riley PR. Use of artificial intelligence to enhance phenotypic drug discovery. Drug Discovery Today. 2021 Apr 1;26(4):887-901.